Utilization of antihypertensives, antidepressants, antipsychotics, and hormones in Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 25, Issue 2, 2011, Pages 144-148

  Zhu, Carolyn W ^a,b   Livote, Elayne E ^a,b   Kahle Wrobleski, Kristin ^c   Scarmeas, Nikolaos ^d,e   Albert, Marilyn ^f   Brandt, Jason ^f   Blacker, Deborah ^g   Sano, Mary ^a,b,h   Stern, Yaakov ^d,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Brookdale Department of Geriatrics   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^e Department of Epidemiology   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; antidepressant; antihypertensive; antipsychotic; hormone; longitudinal studies

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; CHOLINESTERASE INHIBITOR; HORMONE; MEMANTINE; NEUROLEPTIC AGENT;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; COGNITION; DRUG UTILIZATION; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIPSYCHOTIC AGENTS; FEMALE; HORMONES; HUMANS; LONGITUDINAL STUDIES; MALE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 79958255090     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181fcba68     Document Type: Article

References (28)

1. Zhao Y, Kuo TC, Weir S, et al. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Serv Res. 2008;8:108.
2. Lin PJ, Biddle AK, Ganguly R, et al. The concentration and persistence of health care expenditures and prescription drug expenditures in Medicare beneficiaries with Alzheimer's disease and related dementias. Med Care. 2009;47:1174-1179.
3. Zhu CW, Livote E, Kahle-Wrobleski K, et al. Longitudinal medication usage in Alzheimer's disease (AD) Patients. Alzheimer Dis Assoc Disord. 2010. In press.
4. Richards M, Folstein M, Albert M, et al. Multicenter study of predictors of disease course in Alzheimer disease: the "Predictors Study." II. Neurological, psychiatric, and demo-graphic influences on baseline measures of disease severity. Alzheimer Dis Assoc Disord. 1993;7:22-32. (Pubitemid 23127937)
5. Stern Y, Folstein M, Albert M, et al. Multicenter study of predictors ofdisease course in Alzheimer disease: the "Predictors Study." I. Study design, cohort description, and intersite comparisons. Alzheimer Dis Assoc Disord. 1993;7:3-21. (Pubitemid 23127936)
6. Folstein MF, Folstein SE, and McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
7. Stern Y, Sano M, Paulson J, et al. Modified mini-mental state examination: validity and reliability. Neurology. 1987; 37(suppl 1):179.
8. Scarmeas N, Albert M, Brandt J, et al. Motor signs predict poor outcomes in Alzheimer disease. Neurology. 2005;64: 1696-1703. (Pubitemid 40695800)
9. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter ofelderly subjects. Br J Psychiatry. 1968; 114:797-811.
10. Statacorp [Computer Program]. Release 9. Texas, College Station: StataCorp LP; 2005.
11. Mosley WJ, Lloyd-Jones DM. Epidemiology of hypertension in the elderly. Clin Geriatr Med. 2009;25:179-189.
12. Zeglin MA, Pacos J, Bisognano JD. Hypertension in the very elderly: briefreview ofmanagement. Cardiol J. 2009;16: 379-385.
13. Nagai M, Hoshide S, Kario K. Hypertension and dementia. Am JHypertens. 2010;23:116-124.
14. McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;4:CD004034.
15. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008; 7:683-689.
16. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596-608. (Pubitemid 40171242)
17. Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005;62:1601-1608. (Pubitemid 41434568)
18. Scarmeas N, Brandt J, Blacker D, et al. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol. 2007;64: 1755-1761. (Pubitemid 350254938)
19. Hart DJ, Craig D, Compton SA, et al. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease. Int J Geriatr Psychiatry. 2003;18: 1037-1042. (Pubitemid 37479377)
20. US Food and Drug Administration. Information for Health-care Professionals: Conventional Antipsychotics. June 16, 2008 [cited]. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm 124830.htm. Accessed on: May 11, 2009.
21. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943. (Pubitemid 41464695)
22. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353:2335-2341. (Pubitemid 41713745)
23. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257-263. (Pubitemid 27132054)
24. Holtzer R, Scarmeas N, Wegesin DJ, et al. Depressive symptoms in Alzheimer's disease: natural course and temporal relation to function and cognitive status. J Am Geriatr Soc. 2005;53:2083-2089. (Pubitemid 43001187)
25. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmeno-pausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2959-2968. (Pubitemid 38802685)
26. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289:2663-2672. (Pubitemid 37430137)
27. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291: 2947-2958. (Pubitemid 38802684)
28. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000;54:295-301. (Pubitemid 30078056)